AllianceBernstein
APRE icon

AllianceBernstein’s Aprea Therapeutics APRE Stock Holding History

AllianceBernstein’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-680
Closed -$69K – 3323
2021
Q1 		$69K Sell
680
-95
-12% -$11.1K ﹤0.01% 3185
2020
Q4 		$76K Sell
775
-10
-1% -$4.75K ﹤0.01% 3125
2020
Q3 		$378K Sell
785
-40
-5% -$22.4K ﹤0.01% 2680
2020
Q2 		$640K Buy
825
+460
+126% +$302K ﹤0.01% 2452
2020
Q1 		$254K Buy
+365
New +$268K ﹤0.01% 2700

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

AllianceBernstein's APRE Position: Q2 2021 in Review

AllianceBernstein sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 680 shares — an estimated $69K sold.

AllianceBernstein first reported a position in APRE in Q1 2020 and held it in 5 quarters. The position peaked at $640K in Q2 2020. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

  • AllianceBernstein reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AllianceBernstein sold 680 Aprea Therapeutics shares in Q2 2021, an estimated $69K.
  • AllianceBernstein first reported a position in Aprea Therapeutics in Q1 2020 and held it in 5 quarters.
  • AllianceBernstein's Aprea Therapeutics position peaked at $640K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.